Mouse Anti-DOCK1 Recombinant Antibody (D1473) (V2LY-0425-LY764)

Yang, X., Wang, Y., Pang, S., Li, X., Wang, P., Ma, R., ... & Song, C. (2021). LINC00665 promotes the progression of acute myeloid leukemia by regulating the miR-4458/DOCK1 pathway. Scientific reports, 11(1), 1-16.

Cui, W., & Xue, J. (2020). Circular RNA DOCK1 downregulates microRNA‐124 to induce the growth of human thyroid cancer cell lines. Biofactors, 46(4), 591-599.

Liu, P., Li, X., Guo, X., Chen, J., Li, C., Chen, M., ... & Zu, X. (2019). Circular RNA DOCK1 promotes bladder carcinoma progression via modulating circDOCK1/hsa‐miR‐132‐3p/Sox5 signalling pathway. Cell proliferation, 52(4), e12614.

Chiang, S. K., Chang, W. C., Chen, S. E., & Chang, L. C. (2019). DOCK1 regulates growth and motility through the RRP1B-claudin-1 pathway in claudin-low breast cancer cells. Cancers, 11(11), 1762.

Tomino, T., Tajiri, H., Tatsuguchi, T., Shirai, T., Oisaki, K., Matsunaga, S., ... & Uruno, T. (2018). DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1P29S mutation. Biochemical and biophysical research communications, 497(1), 298-304.

Liang, Y., Wang, S., & Zhang, Y. (2018). Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple‑negative breast cancer epithelial cells through the RhoA/Rac1 pathway. Oncology Letters, 16(3), 3481-3488.

Cunningham, R. L., Herbert, A. L., Harty, B. L., Ackerman, S. D., & Monk, K. R. (2018). Mutations in dock1 disrupt early Schwann cell development. Neural development, 13(1), 1-15.

Zhang, B., Li, H., Yin, C., Sun, X., Zheng, S., Zhang, C., ... & Lu, S. (2017). Dock1 promotes the mesenchymal transition of glioma and is modulated by MiR‐31. Neuropathology and Applied Neurobiology, 43(5), 419-432.

Tajiri, H., Uruno, T., Shirai, T., Takaya, D., Matsunaga, S., Setoyama, D., ... & Fukui, Y. (2017). Targeting Ras-driven cancer cell survival and invasion through selective inhibition of DOCK1. Cell reports, 19(5), 969-980.

Lee, S. H., Chiu, Y. C., Li, Y. H., Lin, C. C., Hou, H. A., Chou, W. C., & Tien, H. F. (2017). High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget, 8(42), 72250.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols